ホーム>>Signaling Pathways>> Stem Cell>> Cancer stem cell>>Hexamethylene bisacetamide

Hexamethylene bisacetamide (Synonyms: HMBA, NSC 95580)

カタログ番号GC49027

ヘキサメチレンビスアセトアミドは、腫瘍細胞分化剤です。

Products are for research use only. Not for human use. We do not sell to patients.

Hexamethylene bisacetamide 化学構造

Cas No.: 3073-59-4

サイズ 価格 在庫数 個数
25 g
$58.00
在庫あり
50 g
$109.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents

Hexamethylene bisacetamide is a tumor cell-differentiating agent.1 It induces complete differentiation of 754A murine erythroleukemia cells when used at a concentration of 5 mM. Hexamethylene bisacetamide also induces latent HIV-1 viral production in chronically HIV-1-infected U1 cells in a concentration-dependent manner.2 Implantation of HT-29 colon cancer cells cultured with hexamethylene bisacetamide for seven, but not 28, days reduces tumorigenesis of those cells in mice.3

References:
1.Reuben, R.C., Wife, R.L., Breslow, R., et al.A new group of potent inducers of differentiation in murine erythroleukemia cellsProc. Natl. Acad. Sci. USA73(3)862-866(1976)
2.Contreras, X., Barboric, M., Lenasi, T., et al.HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcriptionPLoS Pathog.3(10)1459-1469(2007)
3.Schroy, P., Winawer, S., and Friedman, E.Effect on in vivo tumorigenicity of lengthy exposure of human colon cancer cells to the differentiation agent hexamethylene bisacetamideCancer Lett.48(1)53-58(1989)

レビュー

Review for Hexamethylene bisacetamide

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Hexamethylene bisacetamide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.